Taxol clinical sponsorship
Executive Summary
HHS is offering a Cooperative Research and Development Agreement (CRADA) to a pharmaceutical manufacturer to "effectively pursue the clinical development" of taxol as an anticancer agent. The National Cancer Institute currently has a two-year supply of taxol for use in clinical trials. In return for providing funding to NCI for the clinical work and collection of raw materials, the pharmaceutical company will receive exclusive rights to the source data from Phase III clinical trials. Isolated from the bark of the Western Yew tree, taxol is believed to have some efficacy in treating ovarian cancer. For further information, contact Dale Shoemaker, NCI, 301/496-7912.
|
HHS is offering a Cooperative Research and Development Agreement
(CRADA) to a pharmaceutical manufacturer to "effectively pursue the
clinical development" of taxol as an anticancer agent. The National
Cancer Institute currently has a two-year supply of taxol for use
in clinical trials. In return for providing funding to NCI for the
clinical work and collection of raw materials, the pharmaceutical
company will receive exclusive rights to the source data from
Phase III clinical trials. Isolated from the bark of the
Western Yew tree, taxol is believed to have some efficacy in
treating ovarian cancer. For further information, contact Dale
Shoemaker, NCI, 301/496-7912. |